UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q/A
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
or
□ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from__________ to _________
Commission File Number 000-52534
PARALLAX HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Nevada | 46-4733512 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
|
1327 Ocean Avenue, Suite B, Santa Monica, CA | 90401 |
(Address of principal executive offices) | (Zip Code) |
|
|
Registrant's telephone number, including area code: | (310) 899-4442 |
|
|
Copy of all Communications to:
Lawrence I. Washor
Washor & Associates
21800 Oxnard Street, Suite 790
Woodland Hills, CA 91367
(310) 479-2660
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
□ YES x NO
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
x YES □ NO
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | □ |
| Accelerated filer | □ |
Non-accelerated filer | □ |
| Smaller reporting company | x |
(Do not check if a smaller reporting company) |
|
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)
□ YES x NO
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
105,566,774 common shares issued and outstanding as of September 30, 2016
EXPLANATORY NOTE
This Amendment No. 1 to the Quarterly Report on Form 10-Q/A is being filed solely to correct the number of shares outstanding as of the last practicable date, above. No other changes have been made to the Form 10-Q, as originally filed on October 13, 2016.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PARALLAX HEALTH SCIENCES, INC. |
|
|
|
|
Dated: October 14, 2016 | /s/ J. Michael Redmond |
| J. Michael Redmond |
| President, Chief Executive Officer and Director |
|
|
|
|
|
|
Dated: October 14, 2016 | /s/ Calli Bucci |
| Calli Bucci |
| Chief Financial Officer |